CSRXP STATEMENT ON ELI LILLY ANNOUNCEMENT ON PRICE OF INSULIN PRODUCTS
Mar 1, 2023
More Big Pharma Companies Should Also Lower Their Insulin Prices… Read More
© 2026 CSRXP- All Rights Reserved
Updates
BIG PHARMA WATCH: NYT REPORT DOCUMENTS NARCOLEPSY DRUG MAKER’S EGREGIOUS EXPLOITATION OF PATENT SYSTEM
Feb 28, 2023
Anti-Competitive Strategy Around Brand Name Narcolepsy Medications Blocked… Read More
BIG PHARMA EARNINGS WATCH: ABBVIE AND ASTRAZENECA
Feb 28, 2023
Big Pharma Giants Once Again Top Wall Street Expectations in Final Round of… Read More
BIG PHARMA EARNINGS WATCH: MERCK, SANOFI, BRISTOL-MYERS SQUIBB AND ELI LILLY
Feb 21, 2023
Four Big Pharma Giants That Hiked Drug Prices on American Patients in 2022 and… Read More
DOSE OF REALITY: BIG PHARMA IS THE CULPRIT BEHIND OUT-OF-CONTROL PRESCRIPTION DRUG PRICES
Feb 16, 2023
Lawmakers Should Focus Attention on Brand Name Drug Companies That Set Prices,… Read More
THEY SAID IT! SENATORS HIGHLIGHT URGENCY TO HOLD BIG PHARMA ACCOUNTABLE TO LOWER DRUG PRICES
Feb 13, 2023
Senate Judiciary Committee Advances Bipartisan Legislation Cracking Down on… Read More
CSRXP APPLAUDS SENATORS FOR BIPARTISAN ACTION TO HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS PATENT ABUSE
Feb 9, 2023
Senate Judiciary Committee Advances Critical Legislation to Crack Down on… Read More
CSRXP APPLAUDS POSITIVE PROGRESS, ENCOURAGES POLICYMAKERS TO ADVANCE ADDITIONAL MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE
Feb 8, 2023
Policies Must Address Big Pharma’s Egregious Practices That Cause High Drug… Read More
BIG PHARMA EARNINGS WATCH: PFIZER, AMGEN, GLAXOSMITHKLINE, NOVARTIS AND JOHNSON & JOHNSON
Feb 6, 2023
Brand Name Drug Companies Kick Off Q4 Earnings Calls After More than 600 Price… Read More
DOSE OF REALITY: SENATE HEARING PROVIDES OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS PATENT ABUSE
Feb 2, 2023
Critical Legislation Targets Anti-Competitive Practices like Patent Thickets… Read More
CSRXP APPLAUDS USPTO EFFORTS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE AND SUPPORTS ADDITIONAL SOLUTIONS TO BOOST COMPETITION TO HELP LOWER DRUG PRICES
Feb 1, 2023
Comment Letters Highlight Key Agency Initiatives Targeting Brand Name Drug… Read More
ICYMI: I-MAK: Cracking Down on Big Pharma’s Patent Abuse to Lower Drug Prices Should Be Bipartisan Priority
Jan 27, 2023
Non-Profit Advocates for Affordable Prescription Drug Prices Call on Congress… Read More